Skip to Content

Abciximab use while Breastfeeding

Drugs containing Abciximab: ReoPro

Medically reviewed by Drugs.com. Last updated on March 5, 2021.

Abciximab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of abciximab during breastfeeding. Because abciximab is a large protein molecule with a molecular weight of 47,615 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, abciximab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. If it is used by a nursing mother, monitor the infant for bruising and bleeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Abciximab

CAS Registry Number

143653-53-6

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Immunoglobulin Fab Fragments

Platelet Aggregation Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.